Cardiovascular protection associated with target of rapamycin inhibitors

Another new study suggesting benefits of rapamycin in cardiovascular protection:

An alteration in extracellular matrix production by vascular smooth muscle cells is a crucial event in the pathogenesis of vascular diseases such as aging-related, atherosclerosis and allograft vasculopathy. The human target of rapamycin (TOR) is involved in the synthesis of extracellular matrix by vascular smooth muscle cells. TOR inhibitors reduce arterial stiffness, blood pressure, and left ventricle hypertrophy and decrease cardiovascular risk in kidney graft recipients and patients with coronary artery disease and heart allograft vasculopathy.

TOR inhibition with rapamycin reduces extracellular matrix production by promoting the change to the contractile phenotype.